Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age

Participants eligible for the study will be randomly allocated (1:1:1) to receive either Luminopia dichoptic treatment while wearing optical correction if needed, Vivid Vision dichoptic treatment while wearing optical correction if needed, or continued optical correction alone if needed, with clinical assessments at 9- and 18-weeks post-randomization. At the 18-week primary outcome visit, participants who were randomly assigned to receive optical correction alone if needed with an IOD of 1 logMAR line (5 letters) or more, will be offered randomization to Luminopia or Vivid Vision dichoptic therapy and if they accept, followed forward with visits at 27- and 36-weeks post-randomization. The study will end for all other participants at 18 weeks.

NCT Number	NCT06524882
Lead Sponsor	Jaeb Center for Health Research Collaborators: National Eye Institute (NEI), Pediatric Eye Disease Investigator Group
Conditions	Amblyopia
Enrollment	252 participants
Start Date	2024-10-22
Primary Completion	2027-07-01 (estimated)
Study Completion	2027-11-01 (estimated)
Updated on ClinicalTrials.gov	2026-02-11